ResMed Swaps Auditors from KPMG to PwC and Names Carol Burt Lead Director
RMD sits 22% above its 52-week low of $180.265.
Summary
ResMed replaced KPMG with PwC as its independent auditor and announced Lead Director Ron Taylor's retirement, with Carol Burt succeeding him in November.
Key Events · Corporate Governance and Compliance · RMD
-
Auditor Change: KPMG Out, PwC In
KPMG was dismissed as independent auditor effective August 13, 2026, and PwC was appointed for the fiscal year ending June 30, 2027. No disagreements or reportable events were reported with KPMG.
-
Lead Director Transition
Ron Taylor will retire from the Board at the 2026 Annual Meeting (expected November 18, 2026). Carol Burt, a director since 2013 and current Nominating and Governance Chair, becomes Lead Director effective November 15, 2026.
-
Clean Auditor Handoff
KPMG's reports on FY2026 and FY2025 financials contained no adverse opinions or qualifications. ResMed states it did not consult PwC on any accounting or auditing matters prior to the appointment.
-
Governance Continuity
The board transition is described as planned and not due to any disagreement. Burt's appointment maintains independent board leadership as the company continues its long-term strategy.
Analysis · RMD · Industrial Applications And Services
ResMed dismissed KPMG as its independent auditor and appointed PwC, effective August 13, 2026. The filing states there were no disagreements or reportable events with KPMG, and no prior consultations with PwC on accounting matters. Separately, long-time Lead Director Ron Taylor will retire at the November 18, 2026 annual meeting, with Carol Burt taking over as Lead Director on November 15. Auditor changes at a $31.8B company always draw scrutiny, but the clean disclosures and planned board succession suggest a routine transition rather than a red flag.
At the time of this filing, RMD was trading at $220.37 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $31.8B. The 52-week trading range was $180.27 to $293.81. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.